Advertisement

Disturbi della giunzione neuromuscolare

  • Carlo Antozzi

Riassunto

I disturbi della giunzione neuromuscolare (GNM) comprendono, in base alla loro eziologia, due gruppi principali di patologie: le forme acquisite, ovvero le canalopatie autoimmuni, e quelle genetiche rappresentate dalle sindromi miasteniche congenite. Le canalopatie autoimmuni sono accomunate, sul piano patogenetico, dalla presenza di autoanticorpi diretti contro differenti canali ionici della terminazione nervosa e comprendono la miastenia grave (MG), la sindrome miasteniforme di Lambert-Eaton (LEMS) e la neuromiotonia acquisita (NM).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Drachman DB. Myasthenia Gravis. N Engl J Med 1994; 330:1797–1810.CrossRefPubMedGoogle Scholar
  2. 2.
    Vincent A, Drachman DB. Myasthenia gravis. Adv Neurol 2002; 88:159–188.PubMedGoogle Scholar
  3. 3.
    Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle & Nerve 2000; 23:453–477.CrossRefGoogle Scholar
  4. 4.
    Vincent A. Unraveling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2:797–804.CrossRefPubMedGoogle Scholar
  5. 5.
    Hoch W, McConville J, Helms S et al. Auto-antibodies to the receptor tyrosine kinase MUSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7:365–368.CrossRefPubMedGoogle Scholar
  6. 6.
    Plested CP, Tang T, Spreadbury I et al. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 2002; 59:1682–1688.PubMedGoogle Scholar
  7. 7.
    Task Force of the Medical Advisory Board of the Myasthenia Gravis Foundation of America; Jaretzki A, Barohn RJ, Ernstoff RM et al. Myasthenia Gravis. Recommendations for clinical research standards. Neurology 2000; 55:16–23.PubMedGoogle Scholar
  8. 8.
    Evoli A, Tonali P, Padua L et al. Clinical correlates with anti-MUSK antibodies in generalized seronegative myasthenia. Brain 2003; 126:2304–2311.CrossRefPubMedGoogle Scholar
  9. 9.
    Sghirlanzoni A, Peluchetti D, Mantegazza R et al. Myasthenia gravis:prolonged treatment with steroids. Neurology 1984; 34:170–174.PubMedGoogle Scholar
  10. 10.
    Mantegazza R, Antozzi C, Peluchetti D et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988; 235:449–453.CrossRefPubMedGoogle Scholar
  11. 11.
    Hohlfeld R, Toyka K, Besinger UA et al. Myasthenia gravis:reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985; 17:238–242.CrossRefPubMedGoogle Scholar
  12. 12.
    Palace J, Newsom-Davis J. Lecky B and the Myasthenia Gravis Study Group. A randomized doubleblind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50:1778–1783.Google Scholar
  13. 13.
    Tindall RS, Rollins JA, Phillips JT et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316:719–724.PubMedGoogle Scholar
  14. 14.
    Chaudhry V, Cornblath DR, Griffin JW et al. Mycophonolate mofetil:a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56:94–96.PubMedGoogle Scholar
  15. 15.
    Ciafaloni E, Massey JM, Tucker-Lipscomb B et al. Mycophenale mofetil for myasthenia gravis. Neurology 2001; 56:97–99.PubMedGoogle Scholar
  16. 16.
    Sanders DB, Hart IK, Mantegazza R et al. An international, phase III, randomized controlled study of mycophenolate mofetil in myasthenia gravis. Neurology, in corso di stampa.Google Scholar
  17. 17.
    Antozzi C, Gemma M, Regi B et al. A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol 1991; 238:103–107.CrossRefPubMedGoogle Scholar
  18. 18.
    Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; 4:CD002–275.Google Scholar
  19. 19.
    Antozzi C, Berta E, Confalonieri P et al. Protein-A immunoadsorption in immunosuppression resistant myasthenia gravis. Lancet 1994; 383:124.CrossRefGoogle Scholar
  20. 20.
    Berta E, Confalonieri P, Simoncini O et al. Removal of antiacetylcholine receptor antibodies by protein A immunoadsorption in myasthenia gravis. Int J Artif Organs 1994; 11:603–608.Google Scholar
  21. 21.
    Howard JF. Intravenous immunoglobulins for the treatment of acquired myasthenia gravis. Neurology 1998; 51 (Suppl 5):S30–S36.PubMedGoogle Scholar
  22. 22.
    Ferrero B, Durelli L. High-dose intravenous immunoglo bulin G treatment of myasthenia gravis. Neurol Sci 2002; 23 (Suppl 1):S9–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Gajdos P, Chevret S, Clair B et al. for the Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41:789–796.CrossRefPubMedGoogle Scholar
  24. 24.
    Stricker RB, Kwiatkowska BJ, Habis JA et al. Myasthenia gravis:response to plasmapheresis following failure of intravenous immunoglobulins. Arch Neurol 1993; 50:837–840.PubMedGoogle Scholar
  25. 25.
    Marx A, Muller-Hermelink HK. From basic immunobiology to the upcoming WHO-Classification of tumors of the thymus. Pathol Res Pract 1999; 195:515–533.PubMedGoogle Scholar
  26. 26.
    Jaretski A III. Thymectomy for myasthenia gravis. Analysis of the controversies regarding technique and results. Neurology 1997; 48 (Suppl 5):S52–S63.Google Scholar
  27. 27.
    Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:7–15.PubMedGoogle Scholar
  28. 28.
    Mantegazza R, Baggi F, Bernasconi P et al. Video-assisted thoracoscopic extended thymectomy and extended transternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients:remission after 6 years of follow-up. J Neurol Sci 2003; 212:31–36.CrossRefPubMedGoogle Scholar
  29. 29.
    Sanders DB. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995; 37 (Suppl 1):S63–73.CrossRefPubMedGoogle Scholar
  30. 30.
    Sanders DB. The Lambert-Eaton myasthenic syndrome. Adv Neurol 2002; 88:189–201.PubMedGoogle Scholar
  31. 31.
    Fukuda T, Motomura M, Nakao Yet al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53:21–28.CrossRefPubMedGoogle Scholar
  32. 32.
    Newsom-Davis J, Murray NMF. Plasmaexchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34:480–485.PubMedGoogle Scholar
  33. 33.
    Bain PG, Motomura M, Newsom-Davis J et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47:678–683.PubMedGoogle Scholar
  34. 34.
    Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs’ syndrome). Report of five cases and literary review. Brain 1993; 116:453–469.CrossRefPubMedGoogle Scholar
  35. 35.
    Liguori R, Vincent A, Clover L et al. Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124:2417–2426.CrossRefPubMedGoogle Scholar
  36. 36.
    Hart IK, Waters C, Vincent A et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997; 41:238–246.CrossRefPubMedGoogle Scholar
  37. 37.
    Vincent A. Understanding neuromyotonia. Muscle Nerve 2000; 23:655–657.CrossRefPubMedGoogle Scholar
  38. 38.
    Hart IK, Maddison P, Newsom-Davis J et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002; 125:1887–1895.CrossRefPubMedGoogle Scholar
  39. 39.
    Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes:progress over the past decade. Muscle & Nerve 2003; 27:4–25.CrossRefGoogle Scholar
  40. 41.
    Congenital myasthenic syndromes:gene mutations. Neuromuscular Disorders 2003; 13:446–448.Google Scholar
  41. 42.
    Goonetilleke A, Harris JB. Clostridial neurotoxins. Journal of Neurology Neurosurgery Psychiatry 2004; 75(Suppl.III):35–39.Google Scholar
  42. 43.
    Pellizzari R, Rossetto O, Schiavo G et al. Tetanus and botulinum neurotoxins:mechanisms of action and therapeutic uses. Phil Trans R Soc Lond 1999; 354:359–368.Google Scholar
  43. 44.
    Cherington M. The clinical spectrum of botulism. Muscle & Nerve 1998; 21:701–710.CrossRefGoogle Scholar
  44. 45.
    Lindstrom M, Korkeala H. Laboratory diagnostics of botulism. Clinical Microbiology Reviews 2006; 19:298–314.CrossRefPubMedGoogle Scholar
  45. 46.
    Bossi P, Tegnell A, Baka A et al. Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism. Euro Surveill 2004; 9 (12) — E13–14. http://www.eurosurveillance.org.PubMedGoogle Scholar
  46. 47.
    F Farrar JJ, Yen LM, Cook T et al. Tetanus. J Neurol Neurosurg Psychiatry 2000; 69:292–301.CrossRefPubMedGoogle Scholar
  47. 48.
    G Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. British Journal of Anesthesia 2001; 87:477–487.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Carlo Antozzi
    • 1
  1. 1.Unità di Neuroimmunologia e Patologia MuscolareFondazione Istituto Neurologico “C. Besta”Milano

Personalised recommendations